Stockscreener 앱 받기
16.62
1.86%
0.3321
전일 마감가:
$16.29
열려 있는:
$16.48
하루 거래량:
4.00M
Relative Volume:
0.35
시가총액:
$19.05B
수익:
$16.54B
순이익/손실:
$-1.64B
주가수익비율:
-11.46
EPS:
-1.45
순현금흐름:
$749.00M
1주 성능:
+3.65%
1개월 성능:
-2.22%
6개월 성능:
-23.85%
1년 성능:
-2.10%
1일 변동 폭
$16.43
$16.65
1주일 범위
$15.95
$16.65
52주 변동 폭
$12.46
$22.80
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
TEVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.61 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ZTS
Zoetis Inc
|
152.47 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.73 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.735 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
UTHR
United Therapeutics Corp
|
303.44 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-05-28 | 개시 | Truist | Buy |
| 2025-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters - The Motley Fool
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World
Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN
Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Canada
There Are Mixed Signals on the Chart for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - uspostnews.com
Digi Power X Inc (DGXX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Market Analysts see Norwegian Cruise Line Holdings Ltd [NCLH] gaining to $21. Time to buy? - dbtnews.com
PG&E Corp [PCG] Revenue clocked in at $24.54 billion, down -14.37% YTD: What’s Next? - dbtnews.com
Greenwave Technology Solutions Inc [GWAV] Is Currently 12.13 above its 200 Period Moving Avg: What Does This Mean? – The DBT News - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Performance and Fundamentals Dashboard tells a completely different story – Sete News - Sete News
Raymond James slashes price target on Adma Biologics Inc [ADMA] – find out why. - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: A Year of Highs and Lows - investchronicle.com
Company’s Banking Stock: Dissecting a 37.52% Quarterly Revenue Decline Amid Growth - investchronicle.com
NEOV’s Market Whiplash: -48.46% YTD Decline, 15.24% Rise in 30 Days - investchronicle.com
Adagio Medical Holdings Inc (ADGM) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
A company insider recently sold 70,961 shares of Teva- Pharmaceutical Industries Ltd. ADR [TEVA]. Should You Sale? - knoxdaily.com
Introducing Our Rant Against Teva- Pharmaceutical Industries Ltd. ADR - uspostnews.com
OS overperforms with a 2.12 increase in share price - uspostnews.com
For Kopin Corp [KOPN], Analyst sees a rise to $2. What next? - dbtnews.com
Market Analysts see Geron Corp [GERN] falling to $2. Time to buy? - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - dbtnews.com
The growth track for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has changed recently - Sete News
Rezolute Inc: Weathering Stock Market Storms with 190.08M Market Cap - investchronicle.com
Ready to Jump After Recent Trade: NIO Inc ADR (NIO) - Sete News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
ORCL’s Stock Journey: What Investors Need to Know About Oracle Corp’s Performance - investchronicle.com
TGB Stock Update: Taseko Mines Ltd’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Lexicon Pharmaceuticals Inc (LXRX) Stock: A Year of Market Fluctuations - investchronicle.com
HESM’s latest rating updates from top analysts. - knoxdaily.com
Analysts review Teva- Pharmaceutical Industries Ltd. ADR’s rating - knoxdaily.com
Zacks Industry Outlook Dr. Reddy's, Sandoz And Teva Pharmaceuticals - Barchart.com
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes - Yahoo Finance
Is Vera Therapeutics Inc (VERA) a threat to investors? - uspostnews.com
What technical indicators reveal about MYGN stock - uspostnews.com
VF Corp (VFC) is a good investment, but the stock may be overvalued - uspostnews.com
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.90%
자본화:
|
볼륨(24시간):